CoPlex Therapeutics, LLC

Biotech · Private

Small molecule therapeutic (BNC-1) that reduces neuroinflammation and amyloid-β production in Alzheimer's disease

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Total capital
$1.7M
Federal grants
$1.7M
3 awards · 2016–2018
Rank in peer group#116 of 326
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

201620172018FEDERAL ↑EQUITY ↓Cumulative $1.7M$106K$1.1M$551K
201620172018FEDERAL ↑EQUITY ↓Cumulative $1.7M$106K$1.1M$551K

Latest events

  • Federal grantHealth and Human S · Phase II · Commercialization of a Novel Therapeutic for Alzheimer's Disease$551K
  • Federal grantHealth and Human S · Phase II · Commercialization of a Novel Therapeutic for Alzheimer's Disease$1.1M
  • Federal grantHealth and Human S · Phase I · Target Identification for Novel Small Molecule Therapeutic for Alzheimer's disease$106K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 326 peers

Line = median

Biotech · Molecule

  • Federal grants#116 · top 36%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • Fawkes Biotechnology, LLCShares a founder: MARK LOVELL
  • PHANES BIOTECH, INC.Similar federal contract value in Biotech · null in contracts
  • NEURANO BIOSCIENCE LLCSimilar federal contract value in Biotech · null in contracts
  • White Dog Labs IncSimilar federal contract value in Biotech · null in contracts
  • MUTAGENTECH, INC.Similar federal contract value in Biotech · null in contracts
  • CALADAN THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .